Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 5
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
5| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10988436 | CUVRIORtrientine tetrahydrochloride | substance | May 2039 |
| 11072577 | CUVRIORtrientine tetrahydrochloride | use | May 2039 |
| 12358861 | CUVRIORtrientine tetrahydrochloride | substance, product | May 2039 |
| 12358862 | CUVRIORtrientine tetrahydrochloride | substance, product | May 2039 |
| 12662445 | CUVRIORtrientine tetrahydrochloride | substance, product | May 2039 |
| Product | Exclusivity | Until |
|---|---|---|
| CUVRIORTRIENTINE TETRAHYDROCHLORIDE | ODE-401 Orphan drug | Apr 2029 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| CUVRIOR | TRIENTINE TETRAHYDROCHLORIDE | tablet, film coated, oral | 81802-001NDA |
Enquiry
Common questions
- Is Orphalan SA FDA approved?
- Orphalan SA holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Orphalan SA make?
- 1 product is listed under Orphalan SA in the openFDA NDC Directory, most often as tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.